Evit Labs, Inc., CEO & CTO David S. Piper will be presenting at the Protein & Peptide Drug Delivery Conference in Boston on Sept. 27th.

Using Shear Force for Pulmonary Delivery: The Performance of the LDI Aerosolization Technology for the Delivery of Antibodies.

McCLELLAN, Calif., July 31, 2002 - EVIT Labs, Inc. today announced David S. Piper, CEO & CTO, will be presenting at the Protein & Peptide Drug Delivery Scientific Advances Enabling Novel Approaches & Improved Products in Boston, MA on Friday, September 27th at 4:00pm. Mr. Piper shall be outlining; Using Shear Force for Pulmonary Delivery: The Performance of the LDI Aerosolization Technology for the Delivery of Antibodies.

Despite recognition of antibodies as promising therapeutic agents for treatment of a number of disease conditions, no means of aerosolization has been used successfully for pulmonary delivery. Recent testing of the Evit Labs' Sonik LDI Technology has shown hat the use of shear force allows for the effective delivery of aerosolized whole antibodies. Testing on IgG, IgA, and IgM families of antibodies demonstrated a preservation of each antibodies binding specificity..

About the Company

Founded in 2000, Evit Labs, Inc., is the leader in sonic delivery of high quality aerosol pharmaceutical, antibodies, proteins and peptides through its patented Sonik LDI (liquid dispensing inhaler. The company offers drug and biotech companies a unique platform in which to deliver treatment to the deep lung.

NOTE: Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements and involve risks and uncertainties. They include our reliance on our collaborative partners and our ability to properly design, implement and complete clinical trial; meet regulatory requirements; demonstrate safety and efficacy of products; manage third-party contracts; and avoid infringement of third- party proprietary rights. Actual results may differ materially from those projected. These forward-looking statements represent our best judgment as of the date of the release. We disclaim any intent or obligation to update these forward-looking statements.